Phase III DASISION and SPIRIT 2 Trials of Dasatinib versus Imatinib in Newly Diagnosed CML in Chronic Phase


Phase III DASISION and SPIRIT 2 Trials of Dasatinib versus Imatinib in Newly Diagnosed CML in Chronic Phase
Slides from presentations at ASH 2014 and transcribed comments from a recent interview with Jorge E Cortes, MD (1/14/15)
Cortes J et al. Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). Proc ASH 2014;Abstract 152.

O’Brien SG et al. Spirit 2: An NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML. Proc ASH 2014;Abstract 517.

Dr Cortes is DB Lane Cancer Research Distinguished Professor for Leukemia Research and Deputy Chairman and Section Chief of AML and CML in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.